RT Journal Article
SR Electronic
T1 COVID-19 in patients with hepatobiliary and pancreatic diseases in East London: A single-centre cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.07.20189621
DO 10.1101/2020.09.07.20189621
A1 Abu Z M Dayem Ullah
A1 Lavanya Sivapalan
A1 Claude Chelala
A1 Hemant M Kocher
YR 2020
UL http://medrxiv.org/content/early/2020/09/09/2020.09.07.20189621.abstract
AB Objective The impact of COVID-19 in patients with pre-existing hepato-pancreato-biliary (HPB) conditions is not clearly understood. To explore risk factors associated with COVID-19 susceptibility and survival in this patient group, we conducted a single-centre retrospective cohort study.Design We interrogated linked electronic health records for patients diagnosed with HPB diseases in East London since 2008 (n = 15 586), and identified 212 confirmed COVID-19 cases between February 12 and June 12, 2020. We conducted risk analyses to identify the effect of demographics, comorbidities and associated medication use, and lifestyle factors and with appropriate adjustment for gender, ethnicity, age group and HPB diagnoses on COVID-19 incidence and mortality.Results We observed an increased risk of COVID-19 for men (Relative Risk, RR = 1.59; 95% CI 1.21 to 2.09) and Black ethnicity (RR = 2.2; 95% CI 1.5 to 3.18). Substance misusers were at more risk of infection, so were patients on Vitamin D treatment. The higher risks associated with South Asian ethnicity, patients with pre-existing nonmalignant pancreatic or liver conditions, age>70, and past smokers were due to coexisting comorbidities; surprisingly current smokers were associated with a lower risk. Increased mortality risk was observed for Black ethnicity (RR = 2.4; 95% CI 1.35 to 3.48), and patients with a pre-existing kidney condition (RR = 2.13; 95% CI 1.16 to 3.55) – particularly when accompanied with an acute episode of renal complications (RR = 2.74; 95% CI 1.32 to 5.13).Conclusions This large multi-ethnic population-based study of HPB patients shows a higher risk of acquiring COVID-19 for male gender, Black ethnicity, medical co-morbidities, and substance mis-users. Particular attention should be paid to patients with a pre-existing kidney disease for further renal insult to prevent fatality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study is conducted under an umbrella study, focusing on the epidemiology of pancreatic and other hepatobiliary cancers in East London, funded by Medical Research Council UK as a UKRI/Rutherford Fellowship to the corresponding author. No additional funding has been received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data utilised for this study were collected and processed under the East London Pancreatic Cancer Epidemiology (EL-PaC-Epidem) study at Barts Helath NHS Trust. The EL-PaC-Epidem study was approved by the East of England - Essex Research Ethics Committee (19/EE/0163; May 17, 2019) and supported by the NHS Confidentiality Advisory Group for collecting and processing confidential patient information without consent (19/CAG/0219; January 17, 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe corresponding author had full access to all the data in the study. All data relevant to the study are included in the article or uploaded as supplementary information. A comprehensive list of codelists and phenotyping algorithms used for the study variables are available on the EL-PaC-Epidem portal (https://pac-epidem-el.bcc.qmul.ac.uk/covid-19). https://pac-epidem-el.bcc.qmul.ac.uk/covid-19